RecruitingPHASE1, PHASE2NCT07293351
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Studying Hereditary clear cell renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- Pumitamig(drug)
- Enrollment
- 234 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2031
Study locations (30)
- Local Institution - 0117, New Haven, Connecticut, United States
- Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
- Local Institution - 0126, Orlando, Florida, United States
- Local Institution - 0124, Iowa City, Iowa, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Local Institution - 0096, Hauppauge, New York, United States
- Local Institution - 0135, Cincinnati, Ohio, United States
- Local Institution - 0127, Cleveland, Ohio, United States
- MUSC Hollings Cancer Center, Charleston, South Carolina, United States
- Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, United States
- Local Institution - 0158, Salt Lake City, Utah, United States
- Local Institution - 0095, Seattle, Washington, United States
- Local Institution - 0154, Buenos Aires, Argentina
- Local Institution - 0156, Buenos Aires, Argentina
- +15 more locations on ClinicalTrials.gov
Collaborators
BioNTech SE
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07293351 on ClinicalTrials.govOther trials for Hereditary clear cell renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07401875A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)M.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT07489534Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal DysfunctionDaihong Liu
- ENROLLING BY INVITATIONNANCT06945640Evaluation of 'RUS NE' in Robot-Assisted Partial Nephrectomy: Efficacy, Safety, and StabilityHutom Corp
- RECRUITINGPHASE2NCT07229040A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.Hospital General Universitario Gregorio Marañon
- RECRUITINGNCT07303725Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional OncologyPalo Alto Veterans Institute for Research
- RECRUITINGNANCT07367750Testing the Feasibility of a Self-Management Support Program for Patient With Chronic Diseases in IsraelUniversity of Haifa
- RECRUITINGPHASE1NCT06623630Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal FunctionWashington University School of Medicine
- RECRUITINGNCT06600646Investigating the Role of ATP Production by Airway Epithelium in Patients With Refractory and Unexplained Chronic Cough (RCC/UCC).McMaster University
See all trials for Hereditary clear cell renal cell carcinoma →